PLx Pharma: Clinical Trials

5 trials sponsored by PLx Pharma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 5
Phase 12Completed 2

Follow PLx Pharma: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects
PL2200, Aspirin tablets - Gastroduodenal Ulceration
Phase 2CompletedPLx Pharma2472012-09-012022-06-07
Clinical Trial Evaluating Gastrointestinal Damage Following Administration PL3100 or Naproxen in At-Risk Adults
PL3100, Naproxen - Gastroduodenal Ulcerations, Erosion
Phase 2CompletedPLx Pharma772010-07-012016-04-11
Oral Bioequivalence Study of PL 3100 and Naproxen in Healthy Adults
Naproxen, PL 3100 - Healthy Volunteers
Phase 1 / Phase 2CompletedPLx Pharma342009-08-012015-09-07
Endoscopic Evaluation of Upper Gastrointestinal (GI) Mucosal Damage Induced by PL-2200 Versus Aspirin in Healthy Volunteers
acetylsalicylic acid - Upper Gastrointestinal Mucosal Damage
Phase 1 / Phase 2CompletedPLx Pharma2042009-01-012015-08-11
Ibuprofen-PC Compared With Ibuprofen in a GI Safety Trial
Ibuprofen-PC - Osteoarthritis
Phase 2CompletedPLx Pharma1252005-01-012008-11-26

Conditions studied

Osteoarthritis (1)

Interventions

Aspirin (2)  ·  Naproxen (2)  ·  aspirin-phosphatidylcholine (1)

Countries

United States (4)

Top investigators

Alan J Kivitz, MD (1)  ·  Byron L Cryer, MD (1)  ·  Frank L Lanza, MD (1)  ·  Howard Schwartz, MD (1)  ·  Michael E Schwartz, DO (1)  ·  Phillip B Miner, MD (1)  ·  Upendra K. Marathi, PhD (1)

NIH funding

1RC3AR059535-01 (1)